Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Diphtheria Antitoxin

Diphtheria Antitoxin: A 2000-Word Comprehensive Blog

Introduction

Diphtheria, a potentially fatal infectious disease caused by Corynebacterium diphtheriae, remains a global public health concern, especially in regions with low vaccination coverage. One of the critical lifesaving treatments for diphtheria is diphtheria antitoxin, a biological product used to neutralize the circulating diphtheria toxin. Though antibiotics are essential to halt the growth of the bacterium, only the antitoxin can prevent further damage caused by the toxin.

Historical Background

The discovery of diphtheria antitoxin in the 1890s marked a milestone in medical history. Emil von Behring, awarded the first Nobel Prize in Physiology or Medicine in 1901, pioneered serum therapy using animal-derived antibodies to treat diphtheria. His work laid the foundation for immunotherapy, and diphtheria antitoxin became the first successful use of passive immunization against a bacterial toxin. In the early 20th century, mass immunization efforts and the use of diphtheria antitoxin significantly reduced mortality. Before the advent of antibiotics, antitoxin was the only effective treatment. Today, despite the availability of vaccines, diphtheria cases still occur, and antitoxin remains a crucial intervention in clinical management.

Composition and Mechanism of Action

Diphtheria antitoxin is composed of polyclonal antibodies, typically derived from the plasma of horses immunized with diphtheria toxoid. These antibodies are capable of binding to and neutralizing the exotoxin produced by Corynebacterium diphtheriae. The exotoxin is responsible for the systemic effects of diphtheria, including myocarditis, neuritis, and renal failure.

The antitoxin works by:

  1. Binding Free Toxin: It neutralizes the circulating toxin in the bloodstream before it enters cells.

  2. Preventing Cellular Entry: By binding the toxin, it blocks its uptake by host cells.

  3. Reducing Morbidity and Mortality: Early administration prevents progression to severe complications.

It's important to note that the antitoxin does not neutralize toxin that has already entered the cells. Hence, timely administration is critical.

Clinical Indications

Diphtheria antitoxin is indicated for:

  • Treatment of confirmed diphtheria (respiratory or cutaneous)

  • Suspected diphtheria cases, especially in regions lacking rapid diagnostic tools

  • Post-exposure prophylaxis in certain high-risk exposures

The antitoxin is administered in conjunction with antibiotics (such as penicillin or erythromycin) to eliminate the bacteria and prevent further toxin production.

Administration and Dosage

Diphtheria antitoxin is administered intravenously or intramuscularly, depending on the severity of the disease and availability of intravenous access. Before administration, patients should undergo a hypersensitivity skin test, as the horse-derived protein can cause severe allergic reactions.

Dosage depends on the severity and duration of the disease:

  • Mild cases: 20,000 to 40,000 units

  • Moderate cases: 40,000 to 60,000 units

  • Severe cases (with extensive pseudomembrane or systemic symptoms): 80,000 to 100,000 units

Early administration is associated with better outcomes. Delayed treatment often fails to prevent complications.

Side Effects and Precautions

The use of equine-derived antitoxin carries the risk of hypersensitivity reactions, including:

  • Serum sickness (fever, rash, arthralgia)

  • Anaphylaxis (rare but potentially fatal)

To mitigate these risks:

  • A sensitivity test is done before full-dose administration.

  • Desensitization protocols can be used if the patient is allergic but antitoxin is essential.

  • Emergency measures (e.g., epinephrine, corticosteroids) should be available.

Other potential side effects include:

  • Local pain at injection site

  • Fever or chills

  • Nausea or vomiting

Despite these risks, the benefits of diphtheria antitoxin in confirmed cases far outweigh the potential side effects.

Production and Availability

Production involves immunizing horses with diphtheria toxoid and harvesting the hyperimmune serum. This process includes:

  1. Toxoid Preparation: Using inactivated diphtheria toxin.

  2. Horse Immunization: Repeated exposure builds up high antibody titers.

  3. Plasma Collection and Purification: Extracted serum is purified to obtain antitoxin.

Due to the complexity and costs involved, few manufacturers produce diphtheria antitoxin globally. This has led to periodic shortages and limited access in some regions. The World Health Organization (WHO) and organizations like UNICEF play a vital role in managing global stockpiles and ensuring supply.

Diphtheria Antitoxin vs. Vaccination

While the antitoxin is critical for treatment, it offers no long-term protection. In contrast, the diphtheria vaccine (as part of DTaP, Tdap, or Td) stimulates the body to produce its own antibodies, providing active immunity.

Key differences:

Feature Diphtheria Antitoxin Diphtheria Vaccine
Immunity Type Passive Active
Onset Immediate Delayed
Duration Short-term Long-term
Use Treatment Prevention

Even after recovery, patients treated with diphtheria antitoxin should be vaccinated, as natural infection does not guarantee lifelong immunity.

Global Health Context

Diphtheria remains endemic in some regions of Africa, Southeast Asia, and Eastern Europe. Outbreaks often occur in refugee camps, conflict zones, or areas with disrupted healthcare systems. The antitoxin is part of the WHO Essential Medicines List, reflecting its critical role in emergency response. Access to diphtheria antitoxin is a matter of public health equity and emergency preparedness.

Notable outbreaks include:

  • Indonesia (2017–2018): Over 900 cases, with WHO intervening to supply antitoxin.

  • Yemen (2017–2022): Ongoing outbreak amid conflict, with over 8,000 suspected cases.

  • Venezuela (2016–2019): Re-emergence linked to low vaccination coverage.

In such scenarios, rapid diagnosis, prompt antitoxin administration, and mass vaccination campaigns are critical.

Challenges and Future Directions

  1. Limited Production Capacity: Only a few countries manufacture diphtheria antitoxin, causing reliance on international aid.

  2. Cold Chain Requirements: Storage and transport at appropriate temperatures are necessary to maintain potency.

  3. Equine Origin Risks: Hypersensitivity reactions and serum sickness remain concerns. Research into human monoclonal antibodies or recombinant antitoxins is ongoing.

  4. Diagnostic Delays: In many settings, diphtheria is underdiagnosed due to limited lab capacity. This delays antitoxin administration.

  5. Training and Awareness: Healthcare providers in non-endemic areas may lack experience with diphtheria, leading to underuse of antitoxin.

Conclusion

Diphtheria antitoxin remains a cornerstone in the treatment of diphtheria, especially in moderate to severe cases. Despite being over a century old, its role is irreplaceable in neutralizing the deadly diphtheria toxin. As the world continues to face outbreaks in vulnerable regions, ensuring the availability and appropriate use of diphtheria antitoxin is essential. While vaccines remain the primary strategy for diphtheria prevention, the antitoxin provides a crucial lifeline in acute clinical management. A global commitment to maintaining production, improving accessibility, and investing in safer alternatives will ensure this life-saving therapy remains available when needed most.

References

  • World Health Organization. Diphtheria Vaccine: WHO Position Paper.

  • Centers for Disease Control and Prevention (CDC). Diphtheria: Clinical Guidance.

  • UNICEF Supply Division. Diphtheria Antitoxin Procurement.

  • Von Behring E. "A New Remedy for Diphtheria." Nobel Lecture, 1901.

  • Global Outbreak Alert and Response Network (GOARN) Reports.